SEPTERNA, INC. COMMON STOCK
NASDAQ: SEPN (Septerna, Inc.)
Last update: 3 hours ago31.37
0.82 (2.68%)
| Previous Close | 30.55 |
| Open | 30.61 |
| Volume | 258,087 |
| Avg. Volume (3M) | 319,317 |
| Market Cap | 1,414,019,456 |
| Price / Earnings (Forward) | 107.53 |
| Price / Sales | 18.45 |
| Price / Book | 3.57 |
| 52 Weeks Range | |
| Earnings Date | 10 Aug 2026 |
| Operating Margin (TTM) | -11,831.05% |
| Diluted EPS (TTM) | -1.78 |
| Quarterly Revenue Growth (YOY) | -30.90% |
| Total Debt/Equity (MRQ) | 6.25% |
| Current Ratio (MRQ) | 32.19 |
| Operating Cash Flow (TTM) | -74.10 M |
| Levered Free Cash Flow (TTM) | -25.69 M |
| Return on Assets (TTM) | -17.20% |
| Return on Equity (TTM) | -30.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Septerna, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.63 |
|
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 2.64% |
| % Held by Institutions | 105.46% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Trv Gp V, Llc | 31 Mar 2026 | 6,215,591 |
| Trv Gp Vi, Llc | 31 Mar 2026 | 4,211,659 |
| 52 Weeks Range | ||
| Median | 35.00 (11.57%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 11 Mar 2026 | 35.00 (11.57%) | Buy | 26.31 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 21 Apr 2026 | CNBC | Amazon launches GLP-1 weight loss program, promising 'fast, convenient' access |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |